	Application No.	Applicant(s)
	10/019,945	CRAWLEY ET AL.
Notice of Allowability	Examiner	Art Unit
	Tamthom N. Truong	1624
The MAILING DATE of this communication appearings being allowable, PROSECUTION ON THE MERITS IS (with (or previously mailed), a Notice of Allowance (PTOL-85) CE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGOROUS OF THE OFFICE OF Upon petition by the applicant. See 37 CFR 1.313	OR REMAINS) CLOSED in or other appropriate commu GHTS. This application is sand MPEP 1308.	this application. If not included nication will be mailed in due course. THIS
This communication is responsive to <u>amendment of 3-10-0-</u>	<u>4</u> .	
The allowed claim(s) is/are 1,6-9,14 and 16.		
The drawings filed on are accepted by the Examiner		
Acknowledgment is made of a claim for foreign priority una) All b) □ Some* c) □ None of the: 1. □ Certified copies of the priority documents have 2. □ Certified copies of the priority documents have 3. □ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received:	been received. been received in Applicatio	n No
olicant has THREE MONTHS FROM THE "MAILING DATE" or ed below. Failure to timely comply will result in ABANDONM S THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file ENT of this application.	a reply complying with the requirements
A SUBSTITUTE OATH OR DECLARATION must be submi INFORMAL PATENT APPLICATION (PTO-152) which give	tted. Note the attached EXA reason(s) why the oath or	MINER'S AMENDMENT or NOTICE OF declaration is deficient.
CORRECTED DRAWINGS (as "replacement sheets") mus a) including changes required by the Notice of Draftsperse 1) hereto or 2) to Paper No./Mail Date b) including changes required by the attached Examiner's Paper No./Mail Date lentifying indicia such as the application number (see 37 CFR 1. ach sheet. Replacement sheet(s) should be labeled as such in the	on's Patent Drawing Review Amendment / Comment or 84(c)) should be written on the	in the Office action of ne drawings in the front (not the back) of
DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT I	sit of BIOLOGICAL MATE	ERIAL must be submitted. Note the
Chment(s) Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 3-10-04 Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview St Paper No./ 8), 7. ⊠ Examiner's	formal Patent Application (PTO-152) Jummary (PTO-413), Mail Date <u>attached</u> . Amendment/Comment Statement of Reasons for Allowance

Application/Control Number: 10/019,945

Art Unit: 1624

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Donald Bird on 05-26-04.

The application has been amended as follows:

Claim 16:

On the first line, delete the phrase "prevention or", and after the phrase 'treatment of', insert -a—, and

On the second line, delete the word "diseases", and insert the word —disease— in its place; also delete the phrase "or medical conditions in a warm-blooded animal in need of such treatment".

Allowable Subject Matter

Applicant's amendment of 03-10-04 has overcome the previous rejections of 112/1st and 2nd paragraphs by deleting non-elected subject matter, and canceling claims 2-5, 10-13, and 15.

With no other outstanding rejection, pending claims 1, 6-9, 14, and 16 are allowed.

Application/Control Number: 10/019,945

Art Unit: 1624

Reason for Allowance

The following is an examiner's statement of reasons for allowance:

The invention is drawn to compounds of substituted quinazolinyl-NR²-C(=O)-NR³-Q², their pharmaceutical composition, and method of treating a T-cell mediated disease.

The closest reference, **Tang et. al. 6,204,267 B1**, teaches two compounds of substituted quinazoline-urea-phenyl. However, those compounds have been excluded from the instant claims. Therefore, the teaching of Tang et. al. no longer anticipates the instant claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 10/019,945

Art Unit: 1624

Information Disclosure Statement

The IDS of 03-10-04 has been considered. The cited references cannot be combined with the teaching of Tang et. al. for a prima facie case of obviousness.

References cited on PTO-892

An updated search yields several references as listed on PTO-892. Although they teach compounds of urea substituted heterocycles, their preferred embodiment is not directed to compounds of substituted quinazoline-urea. Therefore, there is no motivation for one skilled in the art to select the claimed compounds from their generic teachings.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M-F (~ 10 am $\sim 6:30$ pm).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached at 571-272-0674. If you are unable to reach Dr. Shah within a 24 hour period, please contact James O. Wilson, Acting SPE of 1624, at 571-272-0661.

The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

T. Truong

May 26, 2004